FierceBiotechFierceBiotechResearchFierceBiotechITFierceVaccinesFiercePharmaFiercePharmaManufacturing   FierceHealthcare

Free Newsletter

About | Sample | Privacy

Heparin likely weaker, but safer

Tools

Beginning this week, a manufacturing change to the anti-clotting drug heparin will likely decrease its potency, according to an FDA alert.

As a hedge against contamination, following a Baxter recall traced to active ingredient contamination at a plant in China, the United States Pharmacopeia (USP) has adopted new manufacturing controls, which include a modification of the reference standard for the drug's unit dose. The changes match those of the World Health Organization's International Standard (IS) unit dose definition in use in Europe. The revised reference standard and unit definition for heparin is about 10 percent less potent than the former version.

The FDA says that manufacturers for the U.S. market have begun to make heparin using the new USP standard, which became effective October 1, 2009, for production. At FDA request, however, manufacturers have held shipments until at least October 8 to give health care providers and facilities time to make adjustments.

- here's the FDA alert

Related Articles:
Baxter: Tests show suspect heparin was pure
FDA investigating deaths of heparin patients
FDA seizes tainted Celsus heparin
FDA finds 'final link' in heparin case

Bookmark and Share
Get Your FREE FiercePharma Manufacturing Email Newsletter:
Be the first to comment
More stories about FDA guidance   United States Pharmacopeia   Heparin   contamination   China  

Comments

Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

To combat spam, please enter the code in the image.